Equity
Pharmides has made a profit in every financial year since 2022.
Pharmides has made a profit in every financial year since 2022.
The abbreviated format states no turnover.
Green is investment, beige is depreciation.
Short-term debts rose from €2,822 to €4,770.
The last four annual accounts were filed 34 to 43 days before the end of the period.
Higher solvency than 91% of companies in research and development. Sector median 46.1% · 345 companies.
In July 2024, 39,329 companies had the same profile as Pharmides has now. Each dot stands for 99 companies, two years later.
Another 0.1% stopped without a precise date, possibly only after those two years.
The method was tested on the 497,962 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 39,329 companies, not a prediction for Pharmides. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
| Company | ||||
|---|---|---|---|---|
| Pharmides Pelt | €120,762 | €45,701 | 96.0% | - |
| FP-KOMPAS Beveren-Kruibeke-Zwijndrecht | €144,235 | €53,202 | 86.3% | - |
| CVDH – Therapie & Consult Genk | €110,115 | €37,721 | 73.3% | - |
| INDUSTRIAL FUTUR Namur | €144,471 | €62,205 | 67.3% | - |
| HET LAMPJE Leuven | €118,562 | €20,431 | 25.0% | - |
| VSB SOLUTIONS CONSULTING Ecaussinnes | €190,001 | €66,957 | 79.0% | - |
| Op Kindermaat Asse | €59,384 | €36,231 | 6.6% | - |
These companies have the same main activity as Pharmides: scientific research and development (NACE 72200). They are comparable in size and age: total assets between €59,400 and €190,000, founded between 2022 and 2023.
Pharmides files the abbreviated format. That format states no turnover. The gross margin rose from €38,913 in 2022 to €45,701 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
See how customers, suppliers and banks see your own company and what to improve first.
If something looks wrong or is missing, please tell us.